Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Cancer Res. 2014 Oct 27;74(24):7217–7228. doi: 10.1158/0008-5472.CAN-14-0505

Fig. 5. Ligands for RTKs attenuate dasatinib efficacy.

Fig. 5

A and B: Effect of RTK ligands in dasatinib-mediated cell viability reduction. H2286 (A) and HCC366 (B) cells were concomitantly treated with dasatinib and indicated ligands (50 ng/mL for EGF, IGF1, and HGF and 800 ng/mL for GAS6) and then incubated for 72 hours before cell viability assay. Representative triplicates ± SD are presented, which showed similar results at least 3 times. C: p27 expression after dasatinib only or dasatinib (0.5 μM) in combination with RTK ligands (50 ng/mL). Whole cell extracts were prepared 24 hours after treatment.